Program
nerandomilast
Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.
Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.
Drug pageNerandomilast: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 347 open or running | phase 3since Apr 4, 2022 | May 7, 2012 | Apr 15, 2027phase 3 · NCT06806592 |
| Gipfel Life Sciencesits history only | 11 open or running | phase 3since Jan 2, 2026 | Jan 2, 2026 | Jun 30, 2027phase 3 · NCT07321860 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 17 studies since May 7, 2012.
- Aug 6, 2023Named nerandomilastINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BI 1015550
- Oct 2, 20232 phase 1 studies in HealthyNCT06070610, NCT06107036
- Nov 15, 2023Phase 1 study in HealthyNCT06139302 · 12 enrolled · Japan
- Jan 25, 2024Phase 3 study in Idiopathic Pulmonary FibrosisNCT06238622 · 1,666 enrolled · United States, Argentina, Australia and more
- Jan 29, 2024Phase 2 study in Idiopathic Pulmonary FibrosisNCT06241560 · 20 enrolled · United States, Georgia
- Apr 29, 2024Phase 1 study in HealthyNCT06393127 · 64 enrolled · Germany
- May 7, 20242 phase 1 studies in HealthyNCT06408870, NCT06415045
- Oct 1, 2024Phase 1 study in HealthyNCT06624072 · 15 enrolled · Germany
- Jan 28, 2025Phase 3 study in Lung Diseases, InterstitialNCT06806592 · 414 enrolled · United States, Australia, Austria and more
- Jul 22, 20252 phase 1 studies in HealthyNCT07081932, NCT07100964
- Sep 30, 2025Phase 3 study in Lung Diseases, InterstitialNCT07201922 · 80 planned · United States, Argentina, Australia and more
- Jan 23, 2026Phase 3 study in Fibrosing Interstitial Lung DiseaseNCT07366034 · 35 planned · United States, Argentina, Australia and more
- Mar 23, 2026Phase 3 study in Scleroderma, SystemicNCT07497087 · 448 planned · United States, Argentina, Australia and more
- Apr 15, 2026Phase 3 study in Lung Diseases, InterstitialNCT07540988 · 466 planned · United States, Argentina, Australia and more
- Aug 24, 2026Phase 3 study in MyositisNCT07789015 · 270 planned · United States, Argentina, Australia and more
Ahead
- Apr 15, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialNCT06806592
- Apr 28, 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT06238622
- Dec 5, 2028Primary completion: phase 3 study in Lung Diseases, InterstitialNCT07540988
- Apr 27, 2029Primary completion: phase 3 study in Fibrosing Interstitial Lung DiseaseNCT07366034
TargetBeta
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study
Other programs on PDE4B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
All 34 Boehringer Ingelheim leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07789015Myositis · United States, Argentina, Australia and more | 3 | Not yet recruiting | Mar 21, 2030 | 270 |
| NCT07540988Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | Dec 5, 2028 | 466 |
| NCT07497087Scleroderma, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Feb 26, 2030 | 448 |
| NCT07366034Fibrosing Interstitial Lung Disease · United States, Argentina, Australia and more | 3 | Recruiting | Apr 27, 2029 | 35 |
| NCT07201922Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | May 14, 2029 | 80 |
| NCT07100964Healthy · Germany | 1 | Completed | Sep 20, 2025 | 16 |
| NCT07081932Healthy · Germany | 1 | Completed | Sep 27, 2025 | 16 |
| NCT06806592Lung Diseases, Interstitial · United States, Australia, Austria and more | 3 | Active, not recruiting | Apr 15, 2027 | 414 |
| NCT06624072Healthy · Germany | 1 | Completed | Nov 22, 2024 | 15 |
| NCT06415045Healthy · Germany | 1 | Completed | Jul 24, 2024 | 18 |
| NCT06408870Healthy · Germany | 1 | Completed | Aug 28, 2024 | 64 |
| NCT06393127Healthy · Germany | 1 | Completed | Sep 10, 2024 | 64 |
| NCT06241560Idiopathic Pulmonary Fibrosis · United States, Georgia | 2 | Completed | Aug 5, 2026 | 20 |
| NCT06238622Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 28, 2027 | 1,666 |
| NCT06139302Healthy · Japan | 1 | Completed | Feb 7, 2024 | 12 |
| NCT06107036Healthy · United Kingdom | 1 | Completed | Jul 25, 2024 | 46 |
| NCT06070610Healthy · Germany | 1 | Completed | Dec 14, 2023 | 14 |
| NCT05718648Renal Insufficiency · Germany | 1 | Completed | Aug 15, 2023 | 26 |
| NCT05707403Healthy · Netherlands | 1 | Completed | Mar 28, 2023 | 8 |
| NCT05661344Hepatic Insufficiency · Germany | 1 | Completed | Sep 13, 2023 | 28 |
| NCT05633862Healthy · China | 1 | Completed | Mar 16, 2023 | 24 |
| NCT05550636Healthy · Germany | 1 | Completed | Dec 19, 2022 | 15 |
| NCT05428436Healthy · Germany | 1 | Completed | Sep 30, 2022 | 24 |
| NCT05321082Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Completed | Dec 18, 2024 | 1,178 |
| NCT05321069Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Completed | Aug 16, 2024 | 1,177 |
| NCT04771286Healthy · Netherlands | 1 | Completed | May 17, 2021 | 6 |
| NCT04419506Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Completed | Oct 6, 2021 | 147 |
| NCT03542344Healthy · Japan | 1 | Completed | Aug 24, 2018 | 16 |
| NCT03422068Idiopathic Pulmonary Fibrosis · Denmark, Finland, Germany and more | 1 | Completed | Jul 1, 2019 | 15 |
| NCT03403439Healthy · Germany | 1 | Completed | Jul 20, 2018 | 16 |
| NCT03302078Healthy · Germany | 1 | Completed | Dec 13, 2017 | 12 |
| NCT03230487Healthy · Germany | 1 | Completed | Jan 16, 2018 | 42 |
| NCT01835899Healthy · Germany | 1 | Completed | Jun 2013 | 24 |
| NCT01594515Healthy · Germany | 1 | Completed | Sep 2012 | 70 |
How it is read
Names in the registry
- “BI 1015550”, 27 entries
- “Nerandomilast”, 10 entries
- “Nerandomilast formulation 1”, 1 entry
- “Nerandomilast formulation 2”, 1 entry
- “Nerandomilast 18 mg - adult formulation”, 1 entry
Conditions, from the studies’ own filings
- Lung Diseases, Interstitial, 5 studies
- Idiopathic Pulmonary Fibrosis, 5 studies
- Myositis, 1 study
- Scleroderma, Systemic, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.